About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Diverging Treatment Goals Emerge Between Hematologists and Nephrologists in aHUS Care, According to Spherix Global Insights

By: via GlobeNewswire

EXTON, PA, July 17, 2025 (GLOBE NEWSWIRE) -- In the latest Special Topix™: Co-Management Approaches in aHUS (US), Spherix Global Insights explores the nuanced dynamics between hematologists and nephrologists in the management of atypical hemolytic uremic syndrome (aHUS). Based on a quantitative survey of 103 specialists conducted between May and June 2025, the research reveals both shared operational challenges and distinct clinical priorities that shape the current and future treatment landscape.

While both specialties routinely co-manage patients with aHUS, hematologists are more likely to drive treatment decisions, particularly those involving complement inhibition, whereas nephrologists often serve as the initial point of contact due to renal-related symptoms. Across both groups, collaboration is regarded as critical throughout the patient journey, especially given the complexity of diagnosis and treatment coordination,  

Diagnostic uncertainty remains a central obstacle, with both specialties relying on a wide range of laboratory assessments. However, their diagnostic focus diverges: hematologists tend to prioritize hematologic markers such as LDH and platelet counts, while nephrologists place greater emphasis on renal function indicators and secondary triggers like infections or autoimmune conditions.

Complement inhibitors continue to serve as the cornerstone of aHUS management, with high satisfaction reported for Alexion’s Soliris and Ultomiris. Hematologists report broader prescribing experience, including the use and familiarity with biosimilars and Apellis’ Empaveli. In contrast, nephrologists adopt a more holistic approach that frequently incorporates supportive measures such as blood pressure control and dialysis when needed.

Despite current satisfaction levels, both specialties anticipate evolving their treatment approach, with a shift away from Soliris in favor of newer agents expected over the next six months. Hematologists and nephrologists alike express strong interest in Novartis’ oral complement inhibitor Fabhalta (iptacopan), citing convenience of administration and familiarity from its use in other complement-mediated disorders. Nearly half of all respondents report they would consider prescribing Fabhalta within three months of approval.

Looking ahead, treatment goals diverge across specialties: hematologists are more likely to emphasize durable efficacy and extended survival, whereas nephrologists focus more heavily on preserving long-term kidney function. Hematologists also demonstrate higher receptivity to novel mechanisms of action, including NovelMed’s investigational agent ruxoprubart. Nephrologists, while less experienced with biosimilars and emerging therapeutic classes, indicate a growing openness to expanding their understanding of innovative treatment strategies.

Spherix will continue to monitor how these evolving priorities and specialty-specific expectations influence treatment adoption and commercial trajectories as new therapies enter the aHUS market.

About Special Topix™
Special Topix™ is an independent service that includes access to a report or series of reports based on current events or topics of interest in specialty markets covered by Spherix.

About Spherix Global Insights   

Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle.   

The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve with the perspective of the extensive Spherix Physician Community.   

As a trusted advisor and industry thought leader, Spherix’s unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth.   

To learn more about Spherix Global Insights, visit spherixglobalinsights.com or connect through LinkedIn.    

For more details on Spherix’s primary market research reports and interactive dashboard offerings, visit or register here: https://clientportal.spherixglobalinsights.com    

NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and analysis addressed within are based on Spherix Global Insight’s analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release. 


Sarah Hendry, Hematology Franchise Head
Spherix Global Insights
4848794284
sarah.hendry@spherixglobalinsights.com

More News

View More
Pfizer is Locking in New Growth Through a New Acquisition
Via MarketBeat
Topics Artificial Intelligence
Tickers MTSR PFE
Copper Giant Freeport Slumps but Analysts See 33% Upside
Via MarketBeat
Tickers FCX SCCO
The BYD Opportunity: Tesla-Like Growth at a Fraction of the Price
Via MarketBeat
Topics Electric Vehicles
Tickers BYDDY LI TSLA
3 Reasons CoreWeave Could Be the Hottest AI Stock in Q4
Via MarketBeat
Topics Artificial Intelligence
Tickers CRWV NVDA
Accenture: Undervalued GenAI Leader or Snake Eating its Own Tail?
Via MarketBeat
Tickers ACN IBM
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.